Leading Pharmaceutical Company Selects Dendrite to Promote Patient Adherence across its Enterprise

Dendrite International, Inc. (NASDAQ:DRTE) a leading
provider of pharmaceutical industry solutions, today announced that
one of the world's leading pharmaceutical companies has selected
Dendrite to orchestrate patient adherence programs for all
participating brands. The company's decision was based on Dendrite's
complete approach to patient adherence management, an escalating
priority across the US pharmaceutical industry, as companies seek to
close the gap between prescribed therapy and actual patient behavior.
   Three critical strengths underpin Dendrite's comprehensive patient
adherence offering. First, the Dendrite solution reaches an expansive
pharmacy network, with access to approximately 98 percent of the major
retail pharmacies in the U.S. Second, Dendrite's reporting and
analytics capabilities add more precision to a pharmaceutical
company's marketing programs, offering unrivaled depth and breadth of
insight on program effectiveness across multiple channels and
messages. Finally, Dendrite has the unique ability to deliver
communications across multiple channels, based on prescriber and
patient preference.
   "According to recent data, between 15-25 percent of total
prescriptions remain unfilled. Moreover, approximately 30-40 percent
of patients never refill a prescription despite the orders of their
physician," said Carl Cohen, president of Dendrite's Marketing
Solutions division. "This kind of behavior can potentially cause
serious harm to a patient who disregards his or her drug regimen,
while also placing a significant strain on the healthcare system.
Dendrite's goal is to add more precision to pharmaceutical marketing
programs through more closely targeted, tightly orchestrated,
multi-channel campaigns that ultimately leads to better patient
outcomes."

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.